Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414335 | 1.00 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL246482 | 0.91 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL249839 | 0.91 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL249676 | 0.89 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL3414056 | 0.89 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL249592 | 0.89 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL3415150 | 0.89 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL3426444 | 0.88 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL250360 | 0.88 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL3422319 | 0.88 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3CAPIK3CBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588469-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130096134-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2012003271-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096134-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | PIK3CD 1662/4885PIK3CG 2443/4885PIK3CA 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.